Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: Long-term results of the phase III randomized controlled multicenter GRETA trial

G. Mustacchi, R. Ceccherini, S. Milani, A. Pluchinotta, A. De Matteis, L. Maiorino, A. Farris, A. Scanni, F. Sasso, A. Bolognesi, E. Villa, S. Cobelli, C. Boni, A. Zadro, C. Cacioppo, P. Gambrosier, G. Schieppati, P. Sismondi, F. Genta, A. TrainaA. Malloci, M. Mansutti, Carla Dellach, V. Fosser, F. Schittulli

Research output: Contribution to journalArticle

153 Citations (Scopus)

Abstract

Background: To evaluate the efficacy of tamoxifen as primary treatment in women aged over 70 years with operable breast cancer versus surgery followed by adjuvant tamoxifen. Patients and methods: Patients randomly received tamoxifen alone (160 mg day 1, then 20 mg/day) for 5 years or surgery followed by tamoxifen (20 mg/day) for 5 years. Overall survival was the main study end point; secondary objectives included breast cancer survival and local control of the disease. Results: Between 1987 and 1992, 239 patients were assigned to surgery plus tamoxifen and 235 to tamoxifen alone. Treatment arms were comparable for tumor size, clinical nodal status and performance status. At a median follow-up of 80 months 274 patients had died. No difference between groups had emerged in overall and breast cancer survival. There were 27 local progressions in the surgery plus tamoxifen group and 106 in the tamoxifen-alone group (P = 0.0001). In the surgery plus tamoxifen group, no difference in overall survival had emerged according to the extension of operation. Conclusions: The long-term results of the study confirm the 3-year interim analysis already reported. Surgery (radical or minimal) followed by adjuvant tamoxifen does not modify overall and breast cancer survival as compared with tamoxifen alone in early breast cancer of older women. Because of the high rate of local progressions with tamoxifen alone, minimal surgery followed by tamoxifen appears to be the appropriate treatment in such patients. More extensive surgery is not useful. Tamoxifen alone is an adequate alternative treatment in very old or frail patients.

Original languageEnglish
Pages (from-to)414-420
Number of pages7
JournalAnnals of Oncology
Volume14
Issue number3
DOIs
Publication statusPublished - Mar 1 2003

Fingerprint

Tamoxifen
Multicenter Studies
Breast Neoplasms
Survival
Therapeutics

Keywords

  • Breast cancer
  • Elderly
  • Tamoxifen

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly : Long-term results of the phase III randomized controlled multicenter GRETA trial. / Mustacchi, G.; Ceccherini, R.; Milani, S.; Pluchinotta, A.; De Matteis, A.; Maiorino, L.; Farris, A.; Scanni, A.; Sasso, F.; Bolognesi, A.; Villa, E.; Cobelli, S.; Boni, C.; Zadro, A.; Cacioppo, C.; Gambrosier, P.; Schieppati, G.; Sismondi, P.; Genta, F.; Traina, A.; Malloci, A.; Mansutti, M.; Dellach, Carla; Fosser, V.; Schittulli, F.

In: Annals of Oncology, Vol. 14, No. 3, 01.03.2003, p. 414-420.

Research output: Contribution to journalArticle

Mustacchi, G, Ceccherini, R, Milani, S, Pluchinotta, A, De Matteis, A, Maiorino, L, Farris, A, Scanni, A, Sasso, F, Bolognesi, A, Villa, E, Cobelli, S, Boni, C, Zadro, A, Cacioppo, C, Gambrosier, P, Schieppati, G, Sismondi, P, Genta, F, Traina, A, Malloci, A, Mansutti, M, Dellach, C, Fosser, V & Schittulli, F 2003, 'Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: Long-term results of the phase III randomized controlled multicenter GRETA trial', Annals of Oncology, vol. 14, no. 3, pp. 414-420. https://doi.org/10.1093/annonc/mdg117
Mustacchi, G. ; Ceccherini, R. ; Milani, S. ; Pluchinotta, A. ; De Matteis, A. ; Maiorino, L. ; Farris, A. ; Scanni, A. ; Sasso, F. ; Bolognesi, A. ; Villa, E. ; Cobelli, S. ; Boni, C. ; Zadro, A. ; Cacioppo, C. ; Gambrosier, P. ; Schieppati, G. ; Sismondi, P. ; Genta, F. ; Traina, A. ; Malloci, A. ; Mansutti, M. ; Dellach, Carla ; Fosser, V. ; Schittulli, F. / Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly : Long-term results of the phase III randomized controlled multicenter GRETA trial. In: Annals of Oncology. 2003 ; Vol. 14, No. 3. pp. 414-420.
@article{11b2e27ae14b4ed5af645bc9516454b5,
title = "Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly: Long-term results of the phase III randomized controlled multicenter GRETA trial",
abstract = "Background: To evaluate the efficacy of tamoxifen as primary treatment in women aged over 70 years with operable breast cancer versus surgery followed by adjuvant tamoxifen. Patients and methods: Patients randomly received tamoxifen alone (160 mg day 1, then 20 mg/day) for 5 years or surgery followed by tamoxifen (20 mg/day) for 5 years. Overall survival was the main study end point; secondary objectives included breast cancer survival and local control of the disease. Results: Between 1987 and 1992, 239 patients were assigned to surgery plus tamoxifen and 235 to tamoxifen alone. Treatment arms were comparable for tumor size, clinical nodal status and performance status. At a median follow-up of 80 months 274 patients had died. No difference between groups had emerged in overall and breast cancer survival. There were 27 local progressions in the surgery plus tamoxifen group and 106 in the tamoxifen-alone group (P = 0.0001). In the surgery plus tamoxifen group, no difference in overall survival had emerged according to the extension of operation. Conclusions: The long-term results of the study confirm the 3-year interim analysis already reported. Surgery (radical or minimal) followed by adjuvant tamoxifen does not modify overall and breast cancer survival as compared with tamoxifen alone in early breast cancer of older women. Because of the high rate of local progressions with tamoxifen alone, minimal surgery followed by tamoxifen appears to be the appropriate treatment in such patients. More extensive surgery is not useful. Tamoxifen alone is an adequate alternative treatment in very old or frail patients.",
keywords = "Breast cancer, Elderly, Tamoxifen",
author = "G. Mustacchi and R. Ceccherini and S. Milani and A. Pluchinotta and {De Matteis}, A. and L. Maiorino and A. Farris and A. Scanni and F. Sasso and A. Bolognesi and E. Villa and S. Cobelli and C. Boni and A. Zadro and C. Cacioppo and P. Gambrosier and G. Schieppati and P. Sismondi and F. Genta and A. Traina and A. Malloci and M. Mansutti and Carla Dellach and V. Fosser and F. Schittulli",
year = "2003",
month = "3",
day = "1",
doi = "10.1093/annonc/mdg117",
language = "English",
volume = "14",
pages = "414--420",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "NLM (Medline)",
number = "3",

}

TY - JOUR

T1 - Tamoxifen alone versus adjuvant tamoxifen for operable breast cancer of the elderly

T2 - Long-term results of the phase III randomized controlled multicenter GRETA trial

AU - Mustacchi, G.

AU - Ceccherini, R.

AU - Milani, S.

AU - Pluchinotta, A.

AU - De Matteis, A.

AU - Maiorino, L.

AU - Farris, A.

AU - Scanni, A.

AU - Sasso, F.

AU - Bolognesi, A.

AU - Villa, E.

AU - Cobelli, S.

AU - Boni, C.

AU - Zadro, A.

AU - Cacioppo, C.

AU - Gambrosier, P.

AU - Schieppati, G.

AU - Sismondi, P.

AU - Genta, F.

AU - Traina, A.

AU - Malloci, A.

AU - Mansutti, M.

AU - Dellach, Carla

AU - Fosser, V.

AU - Schittulli, F.

PY - 2003/3/1

Y1 - 2003/3/1

N2 - Background: To evaluate the efficacy of tamoxifen as primary treatment in women aged over 70 years with operable breast cancer versus surgery followed by adjuvant tamoxifen. Patients and methods: Patients randomly received tamoxifen alone (160 mg day 1, then 20 mg/day) for 5 years or surgery followed by tamoxifen (20 mg/day) for 5 years. Overall survival was the main study end point; secondary objectives included breast cancer survival and local control of the disease. Results: Between 1987 and 1992, 239 patients were assigned to surgery plus tamoxifen and 235 to tamoxifen alone. Treatment arms were comparable for tumor size, clinical nodal status and performance status. At a median follow-up of 80 months 274 patients had died. No difference between groups had emerged in overall and breast cancer survival. There were 27 local progressions in the surgery plus tamoxifen group and 106 in the tamoxifen-alone group (P = 0.0001). In the surgery plus tamoxifen group, no difference in overall survival had emerged according to the extension of operation. Conclusions: The long-term results of the study confirm the 3-year interim analysis already reported. Surgery (radical or minimal) followed by adjuvant tamoxifen does not modify overall and breast cancer survival as compared with tamoxifen alone in early breast cancer of older women. Because of the high rate of local progressions with tamoxifen alone, minimal surgery followed by tamoxifen appears to be the appropriate treatment in such patients. More extensive surgery is not useful. Tamoxifen alone is an adequate alternative treatment in very old or frail patients.

AB - Background: To evaluate the efficacy of tamoxifen as primary treatment in women aged over 70 years with operable breast cancer versus surgery followed by adjuvant tamoxifen. Patients and methods: Patients randomly received tamoxifen alone (160 mg day 1, then 20 mg/day) for 5 years or surgery followed by tamoxifen (20 mg/day) for 5 years. Overall survival was the main study end point; secondary objectives included breast cancer survival and local control of the disease. Results: Between 1987 and 1992, 239 patients were assigned to surgery plus tamoxifen and 235 to tamoxifen alone. Treatment arms were comparable for tumor size, clinical nodal status and performance status. At a median follow-up of 80 months 274 patients had died. No difference between groups had emerged in overall and breast cancer survival. There were 27 local progressions in the surgery plus tamoxifen group and 106 in the tamoxifen-alone group (P = 0.0001). In the surgery plus tamoxifen group, no difference in overall survival had emerged according to the extension of operation. Conclusions: The long-term results of the study confirm the 3-year interim analysis already reported. Surgery (radical or minimal) followed by adjuvant tamoxifen does not modify overall and breast cancer survival as compared with tamoxifen alone in early breast cancer of older women. Because of the high rate of local progressions with tamoxifen alone, minimal surgery followed by tamoxifen appears to be the appropriate treatment in such patients. More extensive surgery is not useful. Tamoxifen alone is an adequate alternative treatment in very old or frail patients.

KW - Breast cancer

KW - Elderly

KW - Tamoxifen

UR - http://www.scopus.com/inward/record.url?scp=12244294506&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12244294506&partnerID=8YFLogxK

U2 - 10.1093/annonc/mdg117

DO - 10.1093/annonc/mdg117

M3 - Article

C2 - 12598347

AN - SCOPUS:12244294506

VL - 14

SP - 414

EP - 420

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - 3

ER -